BXMPY (Beximco Pharmaceuticals) Other Current Receivables: $5.51 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Beximco Pharmaceuticals Other Current Receivables?

Beximco Pharmaceuticals BXMPY 93 Other Current Receivables is $5.51 Mil as of Mar. 2026. GuruFocus rates BXMPY with a GF Score™ of 93/100. The stock has 5 warning signs investors should review.

Beximco Pharmaceuticals's Other Current Receivables for the quarter that ended in Mar. 2026 was $5.51 Mil.

Beximco Pharmaceuticals's quarterly Other Current Receivables increased from Sep. 2025 ($3.76 Mil) to Dec. 2025 ($6.77 Mil) but then stayed the same from Dec. 2025 ($6.77 Mil) to Mar. 2026 ($5.51 Mil).

Beximco Pharmaceuticals's annual Other Current Receivables increased from Jun. 2023 ($4.00 Mil) to Jun. 2024 ($4.52 Mil) and increased from Jun. 2024 ($4.52 Mil) to Jun. 2025 ($6.52 Mil).

Beximco Pharmaceuticals Other Current Receivables Related Terms

Beximco Pharmaceuticals Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Beximco Pharmaceuticals's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beximco Pharmaceuticals Other Current Receivables Chart

Beximco Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.07 3.41 4.00 4.52 6.52

Beximco Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 6.52 3.76 6.77 5.51

Beximco Pharmaceuticals Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of $5.51 Mil mean?
Beximco Pharmaceuticals (BXMPY) has a Other Current Receivables of $5.51 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Beximco Pharmaceuticals and its competitors.
Is Beximco Pharmaceuticals' Other Current Receivables too high?
Beximco Pharmaceuticals' current Other Current Receivables is $5.51 Mil. Overall, Beximco Pharmaceuticals has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does Beximco Pharmaceuticals' Other Current Receivables compare to ZTS and UTHR?
Beximco Pharmaceuticals' Other Current Receivables of $5.51 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Drug Manufacturers company?
A good Other Current Receivables depends on the Drug Manufacturers industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Beximco Pharmaceuticals and its competitors. Beximco Pharmaceuticals's current Other Current Receivables is $5.51 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beximco Pharmaceuticals stock overvalued right now?
Beximco Pharmaceuticals (BXMPY) has a current Other Current Receivables of $5.51 Mil. The current Other Current Receivables is $5.51 Mil. Beximco Pharmaceuticals' overall GF Score™ is 93/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Beximco Pharmaceuticals (BXMPY), the current Other Current Receivables is $5.51 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Beximco Pharmaceuticals Business Description

Address 19 Dhanmondi, Road No. 7, Dhaka, BGD, 1205
Beximco Pharmaceuticals PLC is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from domestic sales.